Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

IntegriChain Acquires Blue Fin Group

Combining Therapy Commercialization Expertise with Leading Technology, Data, and Business Operations

IntegriChain, delivering Life Sciences’ only comprehensive data and business process platform for market access, today announced that it has acquired Blue Fin Group, a full-service professional management consulting firm delivering research, strategy, and implementation services to help manufacturers optimize access. More than 300 Life Sciences manufacturers – spanning cell and gene therapies, orphan/rare, specialty, primary care, vaccines, biosimilars, and generics – have relied on Blue Fin Group to optimize patient outcomes by orchestrating marketing, market access, field sales, pharmacy and distribution, and patient services as a seamless commercial strategy. Blue Fin Group’s team of nearly 45 consultants and professionals with expertise in market access, drug commercialization, channel strategy, patient funnel pull through, and GTN optimization will operate as an independent division of IntegriChain.

“As the industry contends with ever-increasing payer pressure on access and its gross-to-net distortions continue to grow, this acquisition is perfectly timed,” said Kevin Leininger, CEO of IntegriChain. “Simply put, Blue Fin Group helps develop commercialization strategies, and IntegriChain operationalizes them. Blue Fin Group’s expertise across the market access landscape – from payers to patient services to the channel – is unsurpassed. Their ability to create synergy between access strategy and overall brand strategy is truly differentiated. Combining their expertise with IntegriChain’s technology, data capabilities, and business processes will produce data-driven insights that are more actionable and more impactful for our customers. We welcome Bill and his team of exceptional access experts to our rapidly expanding global team.”

“Today, our two organizations collectively serve hundreds of Life Sciences manufacturers, including all top-30 and the vast majority of new therapy launches,” said William Roth, Founding Partner and President of Blue Fin Group. “Both of our teams are experts in drug commercialization, and the combination of the insights produced by IntegriChain’s ICyte Platform and Blue Fin Group’s breadth of pharma experience places us in an unmatched position. Together we help the industry tackle its two biggest challenges in the era of specialty and precision drug commercialization: converting as much of the patient funnel as possible while optimizing gross-to-net financial performance.”

The entire leadership and all employees of Blue Fin Group will remain with the company under the IntegriChain umbrella, creating a global workforce that spans nearly 600 professionals, including more than 65 consultants in total. Blue Fin Group will remain a separate operating entity going forward, and Blue Fin Group customers should expect no changes or interruptions to the delivery of their solutions and servicing of their accounts. This acquisition is IntegriChain’s fifth expansion since entering its strategic partnership in 2016 with Accel-KKR, a leading technology-focused private equity firm.

Biotechnology News Magazine
Biotechnology News Magazine reports the latest biotech, pharma, FDA updates, biotechnology clinical trials, biotechnology mergers, biotechnology acquisitions, biotechnology funding, articles of interest and other important news.